#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform


Authors: Mustafa Berhuni 1;  Setge Nesime Tıskaoğlu 1;  Cem Ozturkmen 2
Authors place of work: Ersin Arslan Research and Education Hospital, Gaziantep, Turkey 1;  Goznuru Eye Hospital, Gaziantep, Turkey 2
Published in the journal: Čes. a slov. Oftal., 80, 2024, No. Ahead of print, p. 1-3
Category: Kazuistika
doi: https://doi.org/10.31348/2024/21

Summary

Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.

Keywords:

anti-VEGF – optic coherence tomography – adult onset vitelliform dystrophy – retinal dystrophy – subretinal deposits


Zdroje
  1. Gass JD. A clinicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc. 1974;72:139-156.
  2. Chowers I, Tiosano L, Audo I, Grunin M, Boon CJ. Adult-onset foveomacular vitelliform dystrophy: A fresh perspective. Prog Retin Eye Res. 2015;47:64-85.
  3. Grunin M, Tiosano L, Jaouni T, Averbukh E, Sharon D, Chowers I. Evaluation of the association of single nucleotide polymorphisms in the PRPH2 gene with adult-onset foveomacular vitelliform dystrophy. Ophthalmic Genet. 2016;37:285-289.
  4. Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. Retina. 2013;33:513-521.
  5. Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Arevalo JF, Díaz-Llopis M. Primary intravitreal ranibizumab for adult-onset fo veomacular vitelliform dystrophy. Graef Arch Clin Exp Ophthalmol. 2011;249:455-458.
  6. Querques G, Querques L, Leveziel N, Bandello F, Souied EH. Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy. J Fr Ophtalmol. 2013;36:e1-4.
  7. Tiosano L, Jaouni T, Averbukh E, Grunin M, Banin E, Chowers I. Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol. 2014;24:890-896.
  8. Montero JA, Ruiz-Moreno JM, De La Vega C. Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. Eur J Ophthalmol. 2007;17:983-986.
Štítky
Oftalmológia

Článok vyšiel v časopise

Česká a slovenská oftalmologie

Číslo Ahead of print

2024 Číslo Ahead of print
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#